Lower, more frequent cisplatin dosing minimizes hearing loss in head and neck cancer. [PDF]
Fernandez KA +15 more
europepmc +1 more source
Comparison of associations suggests mainly distinct pools of genetic risk factors contribute to cisplatin-induced hearing loss and hearing difficulty in the general population. [PDF]
Shahbazi M +5 more
europepmc +1 more source
Ototoxic impacts of adipose-derived extracts on a murine auditory cell line: molecular insights from proteomic analyses. [PDF]
Olou AA +8 more
europepmc +1 more source
Dexamethasone-loaded lipid-polymeric nanoparticles to improve therapy for cisplatin-induced sensorineural hearing loss. [PDF]
Qi W +5 more
europepmc +1 more source
Single-cell RNA sequencing data analysis of the inner ear in gentamicin-treated mice via intraperitoneal injection. [PDF]
Bao X, Wang Y, Liu W, Tang H, Guo Y.
europepmc +1 more source
Mobile Audiometry for Use in Ototoxicity Monitoring Programs: A Scoping Review. [PDF]
Yim PWC, Lim ZH.
europepmc +1 more source
Oral AZD5438 is a clinically translatable otoprotectant against cisplatin-induced hearing loss. [PDF]
Huang Y +4 more
europepmc +1 more source
From Needle to Sachet: Fosfomycin Versus Amikacin for Cystoscopy Prophylaxis. [PDF]
Quadir U +9 more
europepmc +1 more source
Platinum-Induced Ototoxicity in Pediatric Cancer Patients: A Comprehensive Approach to Monitoring Strategies, Management Interventions, and Future Directions. [PDF]
Ruggiero A +6 more
europepmc +1 more source

